product summary
Loading...
company name :
R&D Systems
product type :
protein
product name :
Recombinant Human Osteoprotegerin/TNFRSF11B Protein, CF
catalog :
185-OS-025/CF
quantity :
25 ug
price :
436 USD
more info or order :
R&D Systems product webpage
citations: 12
Reference
Vorkapic E, Kunath A, Wågsäter D. Effects of osteoprotegerin/TNFRSF11B in two models of abdominal aortic aneurysms. Mol Med Rep. 2018;18:41-48 pubmed publisher
Williams C, Qazi U, Bernstein M, Charniak A, Gohr C, Mitton Fitzgerald E, et al. Mutations in osteoprotegerin account for the CCAL1 locus in calcium pyrophosphate deposition disease. Osteoarthritis Cartilage. 2018;26:797-806 pubmed publisher
Diedisheim M, Oshima M, Albagli O, Huldt C, Ahlstedt I, Clausen M, et al. Modeling human pancreatic beta cell dedifferentiation. Mol Metab. 2018;10:74-86 pubmed publisher
Lane D, Matte I, Laplante C, Garde Granger P, Rancourt C, Piche A. Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis. J Ovarian Res. 2013;6:82 pubmed publisher
Feng Z, He Z, Zhang B, Chen Z. Osteoprotegerin promotes the proliferation of chondrocytes and affects the expression of ADAMTS-5 and TIMP-4 through MEK/ERK signaling. Mol Med Rep. 2013;8:1669-79 pubmed publisher
Wilson T, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487:505-9 pubmed publisher
Mabilleau G, Sabokbar A. Interleukin-32 promotes osteoclast differentiation but not osteoclast activation. PLoS ONE. 2009;4:e4173 pubmed publisher
Chamoux E, Houde N, L Ériger K, Roux S. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J Cell Physiol. 2008;216:536-42 pubmed publisher
Locklin R, Federici E, Espina B, Hulley P, Russell R, Edwards C. Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol Cancer Ther. 2007;6:3219-28 pubmed
Secchiero P, Corallini F, Rimondi E, Chiaruttini C, di Iasio M, Rustighi A, et al. Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells. Blood. 2008;111:1287-94 pubmed
Bogatkevich G, Ludwicka Bradley A, Highland K, Hant F, Nietert P, Singleton C, et al. Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: possible role in systemic sclerosis. Arthritis Rheum. 2007;56:2432-42 pubmed
Tang C, Hsu T, Lin W, Lai M, Yang R, Hsieh S, et al. Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice. J Biol Chem. 2007;282:2346-54 pubmed
product information
brand :
R&D Systems
master code :
185-OS/CF
SKU :
185-OS-025/CF
product name :
Recombinant Human Osteoprotegerin/TNFRSF11B Protein, CF
unit size :
25 ug
seo description :
The Recombinant Human Osteoprotegerin/TNFRSF11B Protein, CF from R&D Systems is derived from NS0. The Recombinant Human Osteoprotegerin/TNFRSF11B Protein, CF has been validated for the following applications: Bioactivity.
target :
Osteoprotegerin/TNFRSF11B
category :
Proteins and Enzymes
buffer :
Lyophilized from a 0.2 ╡m filtered solution in PBS.
conjugate :
Unconjugated
dilution :
Bioactivity
purity :
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie« Blue Staining.
species :
Human
observed molecular weight :
55 kDa, reducing conditions
theoretical molecular weight :
43.5 kDa (monomer)
gene symbol :
TNFRSF11B
details of functionality :
Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L-929 mouse fibroblast cells treated with TRAIL. The ED50 for this effect is 8-24 ng/mL.
endotoxin note :
<0.10 EU per 1 ╡g of the protein by the LAL method.
accessionNumbers :
AAB53709.1
applications :
Bioactivity
source :
NS0-derived Recombinant Human Osteoprotegerin/TNFRSF11B Protein, CF
extended description :
A New and Improved rh OPG is Now Available! The new protein has ~2 fold better activity!
USD :
436 USD
product details :
A New and Improved rh OPG is Now Available! The new protein has ~2 fold better activity!
alt names :
OCIF, OCIFMGC29565, OPG, OPGtumor necrosis factor receptor superfamily member 11B, Osteoclastogenesis inhibitory factor, Osteoprotegerin, TNFRSF11B, TR1, tumor necrosis factor receptor superfamily, member 11b
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, -20 to -70 ░C under sterile conditions after reconstitution.
more info or order :
R&D Systems product webpage
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.